PIK3CD and breast cancer: For example, the NRG1–ERBB4–PI3K–AKT1 pathway mentioned earlier is a cancer therapeutic target, with Herceptin (an anti-ERBB2 monoclonal antibody) used in breast cancer, and other ERBB and PI3K inhibitors under investigation (Fruman and Rommel, 2014).